Wu S, Luo H, Chen W, Liu X, et al. Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients. BMC Cancer 2025;25:845.
PMID: 40346506